study of Zoladex given every 12 weeks versus given every month in Advanced Breast Cancer (ABC) pre-menopausal women

Study identifier:D8664C00008

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks with ZOLADEX 3.6 mg Given every 4 Weeks in Pre-menopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer

Medical condition

Advanced breast cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Goserelin acetate

Sex

Female

Actual Enrollment

98

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Apr 2006
Primary Completion Date: -
Study Completion Date: 01 Nov 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2010 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria